COTA Launches EHR Dataset to Advance Generative AI Models for Cancer Care

COTA, a prominent oncology data and analytics firm, has unveiled Vista, a substantial automated Electronic Health Records (EHR) dataset aimed at expediting cancer research and enhancing the application of reliable generative AI in cancer care. Vista offers biopharmaceutical companies valuable insights from real-world data sources, streamlining the development of life-saving therapies. Leveraging automated data extraction methods, machine learning, and medical expertise, Vista extracts clinically pertinent information from electronic medical records at scale. This transparent approach, overseen by COTA oncologists, ensures precise and relevant data, eliminating the biggest barrier to deploying trustworthy generative AI in cancer therapy. Vista empowers comprehensive patient population insights, facilitating both retrospective analyses and clinical trial patient matching. COTA's CEO, Miruna Sasu, underscores the potential of generative AI to transform cancer treatment with trustworthy large language models and highlights the pivotal role of curated and validated data.

Medigy Insights

COTA, an oncology data and analytics company, has launched Vista, an automated Electronic Health Records (EHR) dataset to expedite cancer research and enable trusted generative AI in cancer care. Vista extracts clinically relevant information from electronic medical records using automation, machine learning, and expert oversight. The goal is to overcome the hurdle of unreliable data, allowing generative AI to transform cancer therapy. Vista aims to provide real-world insights to biopharmaceutical firms, facilitating faster development of life-saving treatments and enhancing patient matching for clinical trials. COTA's CEO, Miruna Sasu, emphasizes the importance of curated and validated data for advancing oncology-focused generative AI models.

Continue reading at hitconsultant.net